目次

1. Personalized Cancer Vaccine: Emerging Immunotherapeutics of the Future
1.1 The Approach Towards Cancer Vaccine Strategy
1.2 Cancer Vaccines - Current Clinical Trials Scenario

2. Personalized Cancer Vaccine Mechanism of Action
2.1 Role of Tumor Neo Antigens and Human Leukocyte Antigen in Personalized Cancer Vaccine
2.1.1 Tumor Neo - Antigens
2.1.2 Human Leukocyte Antigen
2.2 Working Mechanism of Personalized Cancer Vaccine
2.3 Genetic Polymorphism Leading to Pharmacogenomics
2.4 Cancer Pharmacogenomics Observing Somatic Mutations

3. Role of Biomarkers In Personalized Vaccines
3.1 Pharmacogenomic Biomarkers
3.2 Prognostic and Predictive Biomarkers

4. Immune Checkpoint Biomarkers Preventing Tumor Growth
4.1 Emerging Biomarkers for CTLA4
4.2 PD-1/PD-L1

5. Ongoing Market Trends in Personalized Cancer Vaccine Market

6. Personalized Cancer Vaccine: Manufacturing Process and Cost Analysis Study
6.1 Pre Manufacturing Cost Analysis
6.2 Segmented Cost Analysis of Personalized Cancer Vaccine
6.3 Per Patient Cost

7. Emerging Personalized Cancer Vaccines: Clinical Insight and Overview

8. Current Market Trends and Advancements in the Personalized Cancer Vaccine Segment
8.1 Researchers Improving the Outcome of Future Personalized Cancer Vaccine
8.2 Increasing Investments
8.3 Personalized Cancer Vaccine Development using mRNA
8.4 Personalized Cancer Vaccine Market Receiving Collaborations and Ventures Ensure Stable Funding
8.5 DNA Sequencing Technology Development Driving the Personalized Cancer Vaccine Market

9. Global - Personalized Cancer Vaccine Market Segmentation by Cancer Type
9.1 Melanoma
9.2 Lung Cancer
9.3 Breast Cancer
9.4 Colorectal Cancer
9.5 Leukemia
9.6 Prostate Cancer
9.7 Cervical Cancer
9.8 Glioblastoma (Brain Tumor)

10. Personalized Cancer Vaccine: Rising with New Avenues and Opportunities
10.1 Insights into the Personalized Cancer Vaccine Clinical Pipeline
10.2 Opportunities for Personalized Cancer Vaccine in the Emerging Market of the World

11. Porter’s Five Force Analysis of the Personalized Cancer Vaccine Market
11.1 Bargaining Power of Suppliers
11.2 Bargaining Power of Buyer
11.3 Threats of Substitute Products
11.4 Threat of New Entrants to the already Existing Market
11.5 Rivalry Among the Existing Competitors

12. Personalized Cancer Vaccine Market Dynamics
12.1 Favorable Market Parameters
12.2 Challenges Associated with Personalized Cancer Vaccine Market

13. Global Personalized Cancer Vaccine Market Future Outlook

14. Personalized Medicine Market Scenario by Region
14.1 North America
14.2 Latin America
14.3 Europe
14.4 Asia-Pacific
14.4.1 Japan
14.4.2 India
14.4.3 South Korea
14.4.4 Taiwan
14.5 Middle East and Africa

15. Competitive Landscape
15.1 Advaxis
15.2 Avax Technologies
15.3 BioNtech
15.4 Celldex
15.5 CureVac
15.6 Genetech
15.7 Genocea
15.8 Gristone Oncology
15.9 ISA Pharmaceuticals
15.10 Merck
15.11 Moderna Therapeutics
15.12 Neon Therapeutics
15.13 Personalis

List of Figures
Figure 1-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine
Figure 1-2: Advantages of Targeting Neo - Antigens in Cancer Vaccine Production
Figure 2-1: Mechanism of Action of a Personalized Cancer Vaccine
Figure 2-2: Demonstration of Genomic Polymorphism in Pharmacogenomics
Figure 2-3: The Sources of Pharmacological and Pharmacogenetic Variability’s
Figure 3-1: Illustration of Various Types of Biomarkers in Personalized Medicine
Figure 3-2: Roadmap of Development of Predictive Biomarkers
Figure 4-1: High Throughput Immune Assessment for Biomarker Discovery
Figure 5-1: Ongoing Clinical Trials on Personalized Vaccines
Figure 6-1: General Overview of Personalized Cancer Vaccine Production
Figure 6-2: Pre - Manufacturing Cost Analysis for Personalized Cancer Vaccine (US$), 2018
Figure 6-3: Gardasil - Annualized Capital Cost of Production (US$ Million)
Figure 6-4: Cervarix - Annualized Capital Cost of Production (US$ Million)
Figure 6-5: Gardasil - Raw Material Cost Analysis (US$ Million)
Figure 6-6: Cervarix - Raw Material Cost Analysis (US$ Million)
Figure 6-7: Gardasil - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million)
Figure 6-8: Cervarix - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million)
Figure 6-9: Gardasil - Factory and Administrative Overheads (US$ Million)
Figure 6-10: Cervarix - Factory and Administrative Overheads (US$ Million)
Figure 6-11: Gardasil - Manufacturing Cost per single Dose (US$)
Figure 6-12: Cervarix - Manufacturing Cost per single Dose (US$)
Figure 6-13: Personalized Cancer Vaccine - Treatment Cost (US$/Patient)
Figure 6-14: Global - HPV Vaccine Adoption Rate by Regions (%)
Figure 6-15: Gardasil and Gardasil 9 - Cost Analysis (US$), June’2021
Figure 7-1: PGV001 - Phase-I Clinical Trial of PGV001 in Combination With CDX-301 Initiation and Completion Year
Figure 7-2: TG4050 - Phase-I Clinical Trial Initiation and Completion Year in Head and Neck Cancer
Figure 7-3: TG4050 - Phase-I Clinical Trial Initiation and Completion Year in Ovarian Cancer
Figure 7-4: EVX01 - Phase-II Clinical Trial of EVX01 in Combination With Pembrolizumab Initiation and Completion Year
Figure 8-1: Trends and Advancement in the Personalized Cancer Vaccine Segment
Figure 8-2: Investments Generated by Key Market Players in the Personalized Cancer Segment (US$ Million), 2018
Figure 9-1: Global - Non-Melanoma Cancer Incidence and Deaths (000’), 2020
Figure 9-2: Global - Melanoma Cancer Incidence and Deaths (000’), 2020
Figure 9-3: Global - Lung Cancer Incidence and Deaths (Million), 2020
Figure 9-4: Global - Breast Cancer Incidence and Deaths (Million), 2020
Figure 9-5: Global - Colorectal Cancer Incidence and Deaths (Million), 2020
Figure 9-6: Global - Leukemia Incidence and Deaths (000’), 2020
Figure 9-7: Global - Prostate Cancer Incidence and Deaths (000’), 2020
Figure 9-8: Global - Cervical Cancer Incidence and Deaths (000’), 2020
Figure 11-1: Porter’s Five Force Analysis - Overview
Figure 12-1: Driving Factors of the Personalized Cancer Vaccine Market
Figure 12-2: Global - Most Common Types of Cancer by Prevalence, 2018
Figure 12-3: Decrease in the Cost of Human Genome Sequencing (US$/Patient), 2018
Figure 12-4: Time Taken in Whole Genome Sequencing (Months/Patient), 2018
Figure 12-5: Scientific Limitations in Personalized Cancer Vaccine Development
Figure 13-1: Global - Gardasil/ Gardasil 9 Sales (US$ Billion), 2018 -2026
Figure 13-2: Gardasil/ Gardasil 9 - Global Patent Insight
Figure 13-3: Global - Personalized Cancer Vaccine Market Opportunity (US$ Billion), 2021 - 2028
Figure 14-1: US - Total Cancer Deaths, 2016 - 2020
Figure 14-2: Europe - Total Cancer Deaths, 2016 - 2020
Figure 14-3: Asia-Pacific - Total Cancer Deaths, 2020

List of Tables
Table 9-1: Personalized Cancer Vaccine - Ongoing Clinical Trials in Melanoma
Table 9-2: Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer
Table 9-3: Personalized Cancer Vaccine - Ongoing Clinical Trials in Lung Cancer
Table 9-4: Personalized Cancer Vaccine - Ongoing Clinical Trials in Breast Cancer
Table 9-4: Personalized Cancer Vaccine - Ongoing Clinical Trials in Colorectal Cancer
Table 9-5: Personalized Strategies to Attain Target in Acute Myeloid Leukemia